vs
FIRST MID BANCSHARES, INC.（FMBH）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是FIRST MID BANCSHARES, INC.的1.4倍（$127.1M vs $88.2M），再鼎医药同比增速更快（17.1% vs 3.4%），FIRST MID BANCSHARES, INC.自由现金流更多（$124.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 5.0%）
First Mid Bancshares Inc.是一家总部位于美国的区域性金融服务控股公司，提供全品类零售与商业银行产品、财富管理、保险解决方案及农业融资服务，主要服务伊利诺伊、密苏里、印第安纳等美国中西部州的个人、中小企业及农业客户。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
FMBH vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$88.2M
营收增速更快
ZLAB
高出13.7%
3.4%
自由现金流更多
FMBH
多$150.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
5.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $88.2M | $127.1M |
| 净利润 | $23.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 34.0% | -54.6% |
| 净利率 | 26.8% | — |
| 营收同比 | 3.4% | 17.1% |
| 净利润同比 | 23.5% | — |
| 每股收益（稀释后） | $0.98 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FMBHZLAB
| Q4 25 | $88.2M | $127.1M | ||
| Q3 25 | $89.3M | $115.4M | ||
| Q2 25 | $87.5M | $109.1M | ||
| Q1 25 | $84.3M | $105.7M | ||
| Q4 24 | $85.3M | $108.5M | ||
| Q3 24 | $80.6M | $101.8M | ||
| Q2 24 | $79.2M | $100.1M | ||
| Q1 24 | $79.9M | $87.1M |
净利润FMBHZLAB
| Q4 25 | $23.7M | — | ||
| Q3 25 | $22.5M | $-36.0M | ||
| Q2 25 | $23.4M | $-40.7M | ||
| Q1 25 | $22.2M | $-48.4M | ||
| Q4 24 | $19.2M | — | ||
| Q3 24 | $19.5M | $-41.7M | ||
| Q2 24 | $19.7M | $-80.3M | ||
| Q1 24 | $20.5M | $-53.5M |
毛利率FMBHZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率FMBHZLAB
| Q4 25 | 34.0% | -54.6% | ||
| Q3 25 | 32.2% | -42.3% | ||
| Q2 25 | 34.4% | -50.3% | ||
| Q1 25 | 33.4% | -53.3% | ||
| Q4 24 | 29.7% | -62.6% | ||
| Q3 24 | 31.5% | -66.6% | ||
| Q2 24 | 33.7% | -76.0% | ||
| Q1 24 | 33.7% | -80.7% |
净利率FMBHZLAB
| Q4 25 | 26.8% | — | ||
| Q3 25 | 25.2% | -31.2% | ||
| Q2 25 | 26.8% | -37.3% | ||
| Q1 25 | 26.3% | -45.8% | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 24.2% | -40.9% | ||
| Q2 24 | 24.9% | -80.2% | ||
| Q1 24 | 25.6% | -61.4% |
每股收益（稀释后）FMBHZLAB
| Q4 25 | $0.98 | $-0.05 | ||
| Q3 25 | $0.94 | $-0.03 | ||
| Q2 25 | $0.98 | $-0.04 | ||
| Q1 25 | $0.93 | $-0.04 | ||
| Q4 24 | $0.81 | $-0.09 | ||
| Q3 24 | $0.81 | $-0.04 | ||
| Q2 24 | $0.82 | $-0.08 | ||
| Q1 24 | $0.86 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $354.5M | — |
| 股东权益账面价值 | $958.7M | $715.5M |
| 总资产 | $8.0B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资FMBHZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务FMBHZLAB
| Q4 25 | $354.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FMBHZLAB
| Q4 25 | $958.7M | $715.5M | ||
| Q3 25 | $932.2M | $759.9M | ||
| Q2 25 | $894.1M | $791.7M | ||
| Q1 25 | $870.9M | $810.8M | ||
| Q4 24 | $846.4M | $840.9M | ||
| Q3 24 | $858.5M | $667.7M | ||
| Q2 24 | $813.6M | $704.2M | ||
| Q1 24 | $798.0M | $762.2M |
总资产FMBHZLAB
| Q4 25 | $8.0B | $1.2B | ||
| Q3 25 | $7.8B | $1.2B | ||
| Q2 25 | $7.7B | $1.2B | ||
| Q1 25 | $7.6B | $1.2B | ||
| Q4 24 | $7.5B | $1.2B | ||
| Q3 24 | $7.6B | $985.3M | ||
| Q2 24 | $7.6B | $987.4M | ||
| Q1 24 | $7.7B | $988.4M |
负债/权益比FMBHZLAB
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $124.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 140.6% | -21.0% |
| 资本支出强度资本支出/营收 | 7.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.53× | — |
| 过去12个月自由现金流最近4个季度 | $207.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流FMBHZLAB
| Q4 25 | $130.9M | $-26.0M | ||
| Q3 25 | $33.0M | $-32.0M | ||
| Q2 25 | $7.7M | $-31.0M | ||
| Q1 25 | $47.9M | $-61.7M | ||
| Q4 24 | $124.4M | $-55.8M | ||
| Q3 24 | $33.1M | $-26.8M | ||
| Q2 24 | $24.0M | $-42.2M | ||
| Q1 24 | $29.0M | $-90.1M |
自由现金流FMBHZLAB
| Q4 25 | $124.0M | $-26.7M | ||
| Q3 25 | $31.9M | $-35.0M | ||
| Q2 25 | $6.0M | $-33.9M | ||
| Q1 25 | $46.0M | $-63.2M | ||
| Q4 24 | $119.5M | $-58.4M | ||
| Q3 24 | $32.0M | $-28.2M | ||
| Q2 24 | $22.9M | $-42.9M | ||
| Q1 24 | $27.6M | $-91.1M |
自由现金流率FMBHZLAB
| Q4 25 | 140.6% | -21.0% | ||
| Q3 25 | 35.8% | -30.4% | ||
| Q2 25 | 6.8% | -31.1% | ||
| Q1 25 | 54.5% | -59.9% | ||
| Q4 24 | 140.0% | -53.8% | ||
| Q3 24 | 39.7% | -27.7% | ||
| Q2 24 | 28.9% | -42.9% | ||
| Q1 24 | 34.5% | -104.5% |
资本支出强度FMBHZLAB
| Q4 25 | 7.8% | 0.5% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 2.3% | 1.5% | ||
| Q4 24 | 5.8% | 2.4% | ||
| Q3 24 | 1.4% | 1.3% | ||
| Q2 24 | 1.4% | 0.7% | ||
| Q1 24 | 1.9% | 1.1% |
现金转化率FMBHZLAB
| Q4 25 | 5.53× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 2.16× | — | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 1.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FMBH
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
